Fahad Alsaikhan
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 8
- Electrospun Nanofibers in Biomedical Applications 4
- Molecular Medicine top 10%
- Pharmaceutical Science top 10%
-
- MicroRNA in disease regulation 18
- Cancer-related molecular mechanisms research 11
- Pharmacology top 10%
-
- Circular RNAs in diseases 15
- Extracellular vesicles in disease 5
-
- Computational Drug Discovery Methods 5
-
- Nanoplatforms for cancer theranostics 4
- Co-authors
- Abduladheem Turki JalilBagher FarhoodAndrés Alexis Ramírez‐CoronelMoaed E. Al‐GazallyPushpamala RamaiahMaria Jade Catalan OpulenciaJitendra GuptaMustafa M. Kadhim
- Partner nations
- Saudi ArabiaIraqIran
In The Last Decade
Fahad Alsaikhan
100 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 155
- Biomaterials 204
- Molecular Medicine 64
- Pharmaceutical Science 56
- Cancer Research 120
- Pharmacology 68
Countries citing papers authored by Fahad Alsaikhan
This map shows the geographic impact of Fahad Alsaikhan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fahad Alsaikhan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fahad Alsaikhan more than expected).
Fields of papers citing papers by Fahad Alsaikhan
This network shows the impact of papers produced by Fahad Alsaikhan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fahad Alsaikhan. The network helps show where Fahad Alsaikhan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fahad Alsaikhan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 39 | |
| 3 | 2024 | 29 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 17 | |
| 6 | 2024 | 18 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 9 | |
| 10 | 2023 | 9 | |
| 11 | 2023 | 8 | |
| 12 | 2023 | 48 | |
| 13 | 2023 | 2 | |
| 14 | 2023 | 10 | |
| 15 | 2023 | 11 | |
| 16 | 2023 | 8 | |
| 17 | 2022 | 104 | |
| 18 | 2020 | 8 | |
| 19 | 2020 | 5 | |
| 20 | Intralesional OK-432 (Picibanil) Sclerosing Agent in the Treatment of Orbital Lymphangiomas | 2014 | 2 |
About Fahad Alsaikhan
Fahad Alsaikhan is a scholar working on Cancer Research, General Dentistry and Biomaterials, having authored 103 papers that have together received 1.5k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (18 papers), Circular RNAs in diseases (15 papers), Cancer-related molecular mechanisms research (11 papers), Nanoparticle-Based Drug Delivery (8 papers), Computational Drug Discovery Methods (5 papers), Extracellular vesicles in disease (5 papers), Nanoplatforms for cancer theranostics (4 papers) and Electrospun Nanofibers in Biomedical Applications (4 papers). The work is most often cited by research in Biomaterials (204 citations), Molecular Medicine (64 citations) and Pharmaceutical Science (56 citations). Fahad Alsaikhan has collaborated with scholars based in Saudi Arabia, Iraq and Iran. Frequent co-authors include Abduladheem Turki Jalil, Bagher Farhood, Andrés Alexis Ramírez‐Coronel, Moaed E. Al‐Gazally, Pushpamala Ramaiah, Maria Jade Catalan Opulencia, Jitendra Gupta, Mustafa M. Kadhim, Jahidur Rashid and Fakhrul Ahsan. Their work appears in journals such as PLoS ONE, Molecules and International Journal of Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.